Startpage - Formycon AG

1-StartSlider_600x1920

Commercial Stage
Biosimilar Developer

As a globally operating, independent biosimilar developer, Formycon actively contributes to improving patients' access to high-quality, safe and affordable biologic medicines.

LEARN MORE

Latest News

Corporate News

Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships

April 22, 2026

Corporate News

Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026

April 20, 2026

Ad Hoc

Formycon AG announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements

April 15, 2026

Slider_Square_A

Formycon AG –
Commercial Stage
Biosimilars

LEARN MORE

Latest News

Corporate News

Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships

April 22, 2026

Corporate News

Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026

April 20, 2026

Ad Hoc

Formycon AG announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements

April 15, 2026

Key financial figures

Biosimilars

Biosimilar Candidates

Portfolio

Projekt

Technische
Entwicklung

Herstellung

Klinische
Entwicklung

Zulassung

Vermarktung

FYB201

FYB202

FYB203

FYB206

FYB208

FYB209

FYB210

Latest News

Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships

Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026

Formycon AG announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements

Latest News

Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships

Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026

Formycon AG announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements

Key financial figures

Biosimilars

Biosimilar Candidates

Portfolio

#TeamFormycon